EXecutive Registry: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.
Phase of Trial: Phase IV
Latest Information Update: 12 Dec 2012
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 07 Sep 2011 Actual end date Jun 2011 added as reported by ClinicalTrials.gov.
- 07 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Mar 2011 New trial record